CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Patient Input and Clinical Experts: Entyvio

May 5, 2020
CADTH has received the following notice(s) of pending drug submission(s). Brand name Entyvio Generic name vedolizumab Manufacturer Takeda Canada Inc. Indication(s) Crohn’s disease Project Number SR0647-000 Call for patient input 2020-05-05 Patient input deadline ...

What does the evidence say about COVID-19?

April 2, 2020
CADTH is here to answer your questions about COVID-19. We’ve collected relevant information from CADTH and other respected organizations and published it on our new CADTH/COVID-19 web portal. On this site, you’ll find evidence, tools, and resources covering a range of COVID-19 topics including prevention, testing, and treatment. Although some ...

COVID-19: An Update From Dr. Brian O’Rourke, CADTH President and CEO

March 18, 2020
For the latest updates and guidance on COVID-19, please consult the Public Health Agency of Canada. As our country deals with the COVID-19 situation, CADTH has implemented several initiatives to mitigate the risks to our staff and ensure that we continue to support Canada’s health care decision-makers during this period. Public health authorit...

Drug Reimbursement Recommendation - tafamidis (Vyndaqel)

February 21, 2020
Today, CADTH has issued final recommendations for: tafamidis (Vyndaqel) Indications: transthyretin-mediated amyloidosis Recommendation: Reimburse with clinical criteria and/or conditions For more information